Excelimmune, Inc. Awarded Grant from National Institutes of Health (NIH)

Published: Oct 28, 2009

MEDFORD, Mass.--(BUSINESS WIRE)--Excelimmune, Inc. (www.excelimmune.com) announced today that the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant to support research aimed at developing new treatments for Clostridium difficile (C. difficile) infection, employing Excelimmune’s expertise in developing novel antibody therapies for human disease. The SBIR grant will fund a project entitled “The Creation of a Human Recombinant Polyclonal Antibody Therapy against C. difficile,” which will be conducted at Excelimmune’s new facility in Woburn, MA and in consortium with the Roger Williams Medical Center in Providence, RI.

Back to news